Duncan Bridgeman
|
Friday 14th November 2003 |
Text too small? |
However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.
F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.
While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.
The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.
ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha
No comments yet
KMD strengthens balance sheet with debt refinance
GXH - Green Cross Health Limited - Annual Shareholders' Meeting
VGL - Cineplexx Europe signs to Operational Excellence
STU - Steel & Tube - Director Resignation - Steve Reindler
Ryman Healthcare Limited Notice of Meeting 2026
Spark New Zealand FY26 Results Announcement Date
OCA - Oceania bond offer - interest rate set
VNT - Appointment of Managing Director and Group CEO of Ventia
ATM - a2MC declares $300 million special dividend
June 25th Morning Report